2019亚太地区生物技术协作论坛会Bio Partnering APAC 20192019年9月24日-25日Sep.24-25 2019我国·上海市Shanghai, ChinaBiotech Showcase Collection--Final Notification of Bio Partnering APAC 20192019亚太地区生物技术协作论坛会高品质路演公司和新项目锦集公司概况：诺和诺德是技术领先的生物制药公司，在用以糖尿病治疗的甘精胰岛素开发设计和生产制造层面居全球领先水平。诺和诺德公司总部丹麦首都哥本哈根，职工数量30,000人，遍布于70个國家，商品销售遍及179个國家。在殴美诺和诺德均建了生产厂家。电影路演新项目：INNOVO: an open innovation program of Novo Nordisk (INNOVO: 诺和诺德的开放创新新项目)概述:The talk will introduce Novo Nordisk’s open innovation program “INNOVO”. How we want to do drug R&D innovation with external collaboration? What we are looking for? What we can provide to external partners?专题讲座将详细介绍诺和诺德开放创新新项目---INNOVO。 详细介绍诺和诺德怎样根据外界协作加快技术创新新药研发， 期待找寻哪些的外界协作，及其诺和诺德能够为合作方提供哪些。公司概况：中国医药城坐落于江苏省泰州市，是我国首例国家一级药业高新园区，由江苏省人民政府和国家部委（国家科技部、卫健委、中医药管理局、食药品监督管理局）相互基本建设，着眼于健康产业的发展趋势聚集。过去的十余载，早已吸引住很多生物技术公司、医疗器械企业、健康服务公司等再此聚集，主要包括海外500强制药业公司13家（阿斯利康、勃林格殷格翰、雀巢、阿拉宾度制药业等），中国大型企业艾美康淮微生物、金迪克微生物、中崇信诺、亚盛药业、复旦大学合肥肥西、泰康微生物等总共1000好几家，引入60好几家著名高校和药业产品研发组织，國家高档权威专家55名，1100多选“国际性顶级、中国领跑”的药业自主创新成效取得成功落地式申请，中国医药城荣幸变成“國家新式预苗及非特异诊断试剂产业集聚区发展趋势示范点”。Taizhou Medical Hi-tech Industrial Park is a national-level biomedical hi-tech zone, which is jointly constructed by the Jiangsu Provincial People's Government and national ministries (Ministry of Science and Technology, Health and Welfare Committee, Chinese Medicine Authority, Food and Drug Administration) and is dedicated to the development of the bio-industry. In the past years, more than 1000 biopharmaceutical companies have been attracted to gather here, including 13 transnational 500 compulsory drug companies (AstraZeneca, BoehringerIngelheim, Nestle, etc.), domestic famous companies such as Amy Kanghuai Biopharmaceutical (Jiangsu) Co., Ltd.， Jiangsu Jindike Biotechnology Co., Ltd.，ZhongchongXinnuo Biotechnology (Taizhou) Co., Ltd. and Warwick (Jiangsu) Biological Pharmaceutical Co., Ltd.. We have introduced 55 experts of the National Thousand Talents Program, and more than 1,100 "internationally-leading and leading domestic" medical innovations have been successfully declared. We are honor to become "national new vaccines and specific diagnostic reagents."电影路演新项目：系统化产业园区在生物技术改革创新中的作用与功效Function and Impaction of Specialized Parks in the Innovation and Development of Biomedical Industries概述：1 生物医药产业的聚集效用以及区位优势遍布；2 生物技术发展趋势自主创新的重要因素；3 中国医药城的发展史及关键有关公司的改革创新实例；4 中国医药城的系统化服务项目优点，及其从哪一方面协助生物产业改革创新；公司概况：With robust animal data demonstrating anti-angiogenic, anti-inflammatory, and neuroprotective properties, an issued US patent, and seed money, Skyran is ready to complete IND-enabling studies.Skyran uses technology generated at the Penn State College of Medicine by Drs. Joyce Tombran-Tink and Colin Barnstable. The company is a participant in the Phase 1 Ventures program of the University City Science Center, which give us access to matching funds, a number of services, and the Philadelphia life sciences entrepreneurial community.电影路演新项目： Novel drugs to combat eye disease概述 :• Skyran Biologics is an early stage company incorporated in the US that is looking to move most of its operations to China. • Dr. Ji-Ye Wei (president) is currently working full time in China; Drs. Joyce Tombran-Tink and Colin Barnstable currently spend 3-4 months per year working in Tianjin.• Skyran Biologics, Inc. has developed a series of eyedrop formulations to treat dry eye, uveitis, diabetic retinopathy, retinopathy of prematurity and glaucoma.• Dry eye and antibiotic formulations are ready for manufacture.• The diabetic retinopathy treatment is a first in class drug based on patented peptides.公司概况：ZY TherapeuticsInc is committed to addressing this challenge Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of thesoutheastbio-hub.电影路演新项目： Novel Lyophilized Dosage Form of Taxane Formation With Unique Drug Release Profiles概述：Dr. Li has over 10 years of experience working on nanoparticle drug delivery technology in both academic and industry, such as Emory University, UNC Chapel Hill and Nitto Denko Technical.Dr Li was a recognized expert in this field. He was the reviewer of NIH SBIR grant and invited reviewer of several international journals in the field of drug delivery.Dr. Li received his B.S and Ph.D from Hunan University. Dr. Li is the key inventor for the delivery technologies used in ZY Therapeutics Inc.公司概况：Viriom Inc. is a commercial and late-stage biotech company developing novel therapies and prophylactic medicines against HIV-1 and Hepatitis B Virus (HBV). Viriom's pipeline includes: Elpida® (elsulfavirine), the best-in-class NNRTI that obtained first market authorization in 2017; novel fixed doze combination single pill regimens; extended release weekly oral formulations; and long-acting injectable therapy and prophylaxis. Viriom is also developing a highly potent prodrug of the antiviral tenofovir to treat HIV-1 and Hepatitis B patients. Viriom combines its extended release and long-acting injectable compounds with partners’ therapies with curative pote
